Tempest Therapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Global Randomized Phase 1b/2 Clinical Study for Amezalpat2.
Tempest Therapeutics Shares Are Trading Lower. The Company Announced Data From the Ongoing Global Randomized Phase 1b/2 Clinical Study for Amezalpat2.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.